SCHEMBL7085296

SCHEMBL7085296

Cc1ccc(C(=O)C(=O)c2cccc(-c3ccc(F)cc3)c2-c2cccs2)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER2 P43116 3/20 0.40
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
HTR2A P28223 1/20 0.36
TNFRSF1A P19438 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2C9 P11712 3/20 0.35
CYP2C19 P33261 3/20 0.35
MEN1 O00255 2/20 0.35
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP3A4 P08684 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 4/20 0.35
POLB P06746 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089421 0.90 PTGER2 (0.41) PTGER2ABL1BCRTNFRSF1ACYP1A2
SCHEMBL7085178 0.82 PTGER2 (0.38) PTGER2ABL1BCRNPC1RAB9A
SCHEMBL7085151 0.80 PTGS2 (0.41) PTGS1
SCHEMBL7090744 0.73 SLC6A4 (0.41) ABL1MEN1KMT2AKDM4EMAPT
SCHEMBL7089414 0.73 PTGER2 (0.39) PTGER2ABL1BCRTNFRSF1ACYP1A2
SCHEMBL7486572 0.72 HCRTR1 (0.41) TNFRSF1ANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL7088117 0.71 ALDH1A1 (0.52) NPC1RAB9ASMN1; SMN2MEN1GAA
SCHEMBL7085446 0.68 SLC6A4 (0.40) SMN1; SMN2MAPTPOLBTP53ALDH1A1
SCHEMBL27858414 0.67 PTGER2 (0.53) PTGER2ABL1BCRTNFRSF1ANPC1
SCHEMBL6300223 0.65 KCNH2 (0.50) RAB9AMEN1GAAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 PTGER2 386/4885ABL1 327/4885BCR 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.